PALO ALTO, CA, December 03, 2025 /24-7PressRelease/ -- DFriedhelm Blobel has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Blobel has established a distinguished career in the biopharmaceutical industry, marked by leadership roles and significant achievements across multiple continents. Since 2023, he has served as a board member of IDP Pharma in Barcelona, Spain, where he contributes his expertise to advancing innovative therapies. Beginning in 2019, Dr. Blobel also became a board member at ImaginAb in Los Angeles, California, supporting the company's mission to develop next-generation imaging agents for immuno-oncology.

In 2018, Dr. Blobel joined Life Science Angels in Palo Alto, California, as a member. In this capacity, he reviews proposals and evaluates companies seeking funding, leveraging his extensive experience to guide investment decisions in the life sciences sector. His involvement with Life Science Angels reflects his commitment to fostering innovation and supporting early-stage ventures.

Since 2017, Dr. Blobel has served as chief executive officer of BIOBLOC in Palo Alto, California. Under his leadership, the company has pursued advancements in biotechnology solutions. Concurrently, from 2017 to 2020, he served as an independent director for SciClone Pharmaceuticals in the Cayman Islands and Hong Kong. This role followed his notable tenure as chief executive officer, president, and board member of SciClone Pharmaceuticals in Foster City, California, a Nasdaq listed company from 2006 to 2017.

Dr. Blobel considers his leadership at SciClone Pharmaceuticals among his most significant accomplishments. Over twelve years, he guided the publicly listed company, originally incorporated in Delaware and headquartered in California, through its operations and focused it largely on China. He oversaw the development of a robust sales force of 600 employees within China and facilitated successful partnerships with Western companies seeking market entry. In 2017, Dr. Blobel managed the sale of SciClone to Chinese financial investors for over $600 million, after which he remained on the board for one year. The transaction was particularly notable given the company's profitable product portfolio and strong market position.

Before his work at SciClone Pharmaceuticals, Dr. Blobel was chief executive officer at Gryphon Therapeutics from 2000 to 2005, where he led efforts to develop novel therapeutic approaches. From 1996 to 1999, he served as chief technology officer at Dade Behring, contributing to technological advancements within the diagnostics industry.

Dr. Blobel's expertise in biopharmaceuticals is widely recognized and has been shaped by his global professional journey. He has lived and worked for eight years each in Europe and Tokyo, Japan, before spending more than two decades in the United States. This international experience has given him a broad perspective and a deep understanding of diverse markets and cultures.

His academic foundation includes a Doctor of Science (Dr.rer.nat.) in biochemistry and microbiology from the University of Hohenheim in Germany. Dr. Blobel credits his success to remaining grounded and persistent throughout his career. He also attributes his achievements to his extensive international experience, which has fostered patience and equipped him with a wide range of problem-solving strategies.

Beyond his professional pursuits, Dr. Blobel is committed to civic engagement as a supporter and donor for Parkinson's disease treatment initiatives. His philanthropic efforts reflect a dedication to advancing medical research and improving patient outcomes.

On a personal level, Dr. Blobel is the father of three children and enjoys traveling and skiing during his leisure time. Looking ahead, he is focused on facilitating successful exits for early-stage companies affected by recent global challenges and on connecting these ventures with key financial partners. Additionally, he is dedicated to securing funding for products that address Parkinson patients needs and to bringing impactful therapies to market, underscoring his ongoing commitment to benefiting patients through innovation in biotechnology.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #